Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283491 | 0.95 | CHRM1 (0.40) | CHRM1DRD2DRD4DRD3 | |
| SCHEMBL13705332 | 0.89 | CHRM1 (0.44) | CHRM1RENCYP3A4 | |
| SCHEMBL4292144 | 0.84 | CHRM1 (0.43) | CHRM1DRD2DRD4DRD3REN | |
| SCHEMBL13705333 | 0.84 | CHRM1 (0.42) | CHRM1 | |
| SCHEMBL4284610 | 0.79 | REN (0.44) | DRD2DRD3REN | |
| SCHEMBL4283298 | 0.79 | CHRM1 (0.40) | CHRM1DRD2DRD4DRD3 | |
| SCHEMBL4285458 | 0.76 | KDM4E (0.41) | DRD2DRD3REN | |
| SCHEMBL4288580 | 0.76 | MAOA (0.51) | DRD2DRD4DRD3CYP3A4 | |
| SCHEMBL13705318 | 0.75 | CHRM1 (0.46) | CHRM1DRD2DRD4DRD3REN | |
| SCHEMBL4752088 | 0.74 | DRD3 (0.38) | DRD3REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CHRM1 3125/4885DRD2 3802/4885DRD4 3213/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CHRM1 3125/4885DRD2 3802/4885DRD4 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.